Seminars in arthritis and rheumatism · 2025
Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dieudé Philippe, Sparks Jeffrey A, Fischer Aryeh, Chen Leo, Lozenski Karissa, Dahan Stephanie, Chaballa Mark, Little Wayne
Аннотация
BACKGROUND: Interstitial lung disease (ILD) is a common and serious complication of rheumatoid arthritis (RA) and is associated with increased morbidity, mortality, and healthcare resource utilization.
OBJECTIVE: To determine incidence rates (IRs) of ILD events in patients enrolled in clinical trials for RA who received abatacept + methotrexate (MTX) versus placebo + MTX.
METHODS: We performed a retrospective analysis of pooled safety data from 10 phase 3 clinical trials of adult patients. ILD events included acute respiratory events suggestive of pneumonitis/ILD. Crude IRs per 100 person-years for baseline demographics and disease characteristics within treatment groups and IR ratios (IRRs) for placebo + MTX versus abatacept + MTX were estimated.
RESULTS: Overall, 3708 (10,521 person-years) were treated with abatacept + MTX and 999 patients were treated with placebo + MTX (938 person-years). Patients treated with abatacept + MTX had a lower rate of ILD events versus patients treated with placebo + MTX: IR (95 % CI) 0.10 (0.05-0.18) versus 0.43 (0.16-1.14), respectively (IRR [95 % CI] 4.49 [1.23-13.42] for placebo + MTX vs abatacept + MTX). Patients with RA aged ≥ 55 years, body mass index < 30 kg/m2, no history of smoking, no baseline disease-modifying antirheumatic drug use other than MTX, no prior tumor necrosis factor inhibitor use, high DAS28-CRP, and rheumatoid factor or anti-citrullinated protein antibody positivity who were receiving corticosteroid(s) had a significantly lower rate of ILD events if treated with abatacept + MTX versus placebo + MTX.
CONCLUSION: In this post hoc analysis, patients with RA who received abatacept had a lower rate of ILD events, including the subgroups of older age, lower body mass index, and no smoking history, compared with placebo. This warrants further investigation in prospective, controlled studies.
OBJECTIVE: To determine incidence rates (IRs) of ILD events in patients enrolled in clinical trials for RA who received abatacept + methotrexate (MTX) versus placebo + MTX.
METHODS: We performed a retrospective analysis of pooled safety data from 10 phase 3 clinical trials of adult patients. ILD events included acute respiratory events suggestive of pneumonitis/ILD. Crude IRs per 100 person-years for baseline demographics and disease characteristics within treatment groups and IR ratios (IRRs) for placebo + MTX versus abatacept + MTX were estimated.
RESULTS: Overall, 3708 (10,521 person-years) were treated with abatacept + MTX and 999 patients were treated with placebo + MTX (938 person-years). Patients treated with abatacept + MTX had a lower rate of ILD events versus patients treated with placebo + MTX: IR (95 % CI) 0.10 (0.05-0.18) versus 0.43 (0.16-1.14), respectively (IRR [95 % CI] 4.49 [1.23-13.42] for placebo + MTX vs abatacept + MTX). Patients with RA aged ≥ 55 years, body mass index < 30 kg/m2, no history of smoking, no baseline disease-modifying antirheumatic drug use other than MTX, no prior tumor necrosis factor inhibitor use, high DAS28-CRP, and rheumatoid factor or anti-citrullinated protein antibody positivity who were receiving corticosteroid(s) had a significantly lower rate of ILD events if treated with abatacept + MTX versus placebo + MTX.
CONCLUSION: In this post hoc analysis, patients with RA who received abatacept had a lower rate of ILD events, including the subgroups of older age, lower body mass index, and no smoking history, compared with placebo. This warrants further investigation in prospective, controlled studies.